TABLE 2.
Positivity rates of SARS-CoV-2 antibody assays according to the characteristics of the participantsa
| Characteristic (n) | Roche assay |
Abbott assay |
Siemens assay |
SD Biosensor assay |
GenScript assay |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positivity ratea | P valueb | Positivity rate | P value | Positivity rate | P value | Positivity rate | P value | Positivity rate | P value | |
| Before vaccination (228) | 0 (0.0) | 1 (0.4) | 0 (0.0) | 2 (0.9) | 0 (0.0) | |||||
| After 1st vaccination (228) | 193 (84.6) | 211 (92.5) | 172 (75.4) | 206 (90.7) | 151 (66.2) | |||||
| Sex | 0.442 | 0.827 | 0.437 | 0.404 | 0.407 | |||||
| Male (36) | 32 (88.9) | 33 (91.7) | 29 (80.6) | 34 (94.4) | 26 (72.2) | |||||
| Female (192) | 161 (83.9) | 178 (92.7) | 143 (74.5) | 172 (89.6) | 125 (65.1) | |||||
| Age | 0.686 | 0.586 | 0.685 | 0.925 | 0.828 | |||||
| 21–30 (101) | 85 (84.2) | 95 (94.1) | 76 (75.2) | 91 (90.1) | 70 (69.3) | |||||
| 31–40 (50) | 43 (86.0) | 44 (88.0) | 39 (78.0) | 45 (90.0) | 31 (62.0) | |||||
| 41–50 (46) | 37 (80.4) | 43 (93.5) | 32 (69.6) | 41 (89.1) | 30 (65.2) | |||||
| 51–60 (31) | 28 (90.3) | 29 (93.5) | 25 (80.6) | 29 (93.5) | 20 (64.5) | |||||
| Occupation | 0.143 | 0.508 | 0.154 | 0.284 | 0.160 | |||||
| Doctor (14) | 14 (100.0) | 14 (100.0) | 13 (92.9) | 14 (100.0) | 13 (92.9) | |||||
| Nurse (154) | 127 (82.5) | 140 (90.9) | 110 (71.4) | 136 (88.3) | 98 (63.6) | |||||
| Laboratory technician (58) | 51 (87.9) | 55 (94.8) | 47 (81.0) | 54 (93.1) | 39 (67.2) | |||||
| Others (2) | 1 (50.0) | 2 (100.0) | 2 (100.0) | 2 (100.0) | 1 (50.0) | |||||
| Days after 1st vaccination | 0.004 | 0.025 | 0.008 | 0.049 | 0.010 | |||||
| 11–20 (179) | 145 (81.0) | 162 (90.5) | 128 (71.5) | 158 (88.3) | 111 (62.0) | |||||
| 21–28 (49) | 48 (98.0) | 49 (100.0) | 44 (89.8) | 48 (98.0) | 40 (81.6) | |||||
| Adverse reactions after 1st vaccination | 0.809 | 0.479 | <0.001 | 0.510 | 0.018 | |||||
| Absent (8) | 7 (87.5) | 7 (87.5) | 2 (25.0) | 7 (87.5) | 3 (37.5) | |||||
| Mild (152) | 127 (83.6) | 139 (91.4) | 111 (73.0) | 135 (88.8) | 95 (62.5) | |||||
| Severe (68) | 59 (86.8) | 65 (95.6) | 59 (86.8) | 64 (94.1) | 53 (77.9) | |||||
| Duration (days) of adverse reactions | 0.011 | <0.001 | 0.002 | <0.001 | 0.191 | |||||
| <1 (59) | 43 (72.9) | 48 (81.4) | 36 (61.0) | 46 (78.0) | 35 (59.3) | |||||
| 2–3 (141) | 124 (87.9) | 136 (96.5) | 116 (82.3) | 133 (94.3) | 97 (68.8) | |||||
| >4 (20) | 19 (95.0) | 20 (100.0) | 18 (90.0) | 20 (100.0) | 16 (80.0) | |||||
| Antipyretics | 0.350 | 0.550 | 0.858 | 0.392 | 0.411 | |||||
| Taken (205) | 172 (83.9) | 189 (92.2) | 155 (75.6) | 184 (89.8) | 134 (65.4) | |||||
| Not taken (23) | 21 (91.3) | 22 (95.7) | 17 (73.9) | 22 (95.7) | 17 (73.9) | |||||
aPositivity rates are expressed as number (percent).
bP values of <0.05 are given in boldface.